ARCHIVES

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

This article is from The Cancer Letter archive.

Vol. 11 No. 14 | April 5, 1985

Download PDF Visit The Full Archive

Related Articles

Rescission Cuts $5-6 Mil. From NCI FY94 Appropriations , Affects Intramural Program

March 11, 1994

ASCO Urges Increase In Research Funding, Removal of Barriers For Trial Participation

January 23, 2009

In Brief: Calabresi: Rimer: Outstanding ”For NCAB Chair; board Should Maintain Strong Leadership Role

September 23, 1994

FA Drug Approval on Activity, Rather Than Survival Urged By NCU

January 13, 1989

NCI Cooperative Group Clinical Trials Approved

October 30, 2009

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

May 25, 2001